These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2565958)

  • 21. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects.
    Fujimura A; Ebihara A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1994 Mar; 34(3):260-5. PubMed ID: 8021335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of intravenous and nasal bioavailability of clonidine in rodents.
    Babhair SA; Tariq M; Abdullah ME
    Res Commun Chem Pathol Pharmacol; 1990 Feb; 67(2):241-8. PubMed ID: 2333412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonidine through the skin in the treatment of essential hypertension: is it practical?
    Groth H; Vetter H; Knüsel J; Boerlin HJ; Walger P; Baumgart P; Wehling M; Siegenthaler W; Vetter W
    J Hypertens Suppl; 1983 Dec; 1(2):120-2. PubMed ID: 6599488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches.
    Shah VP; Tymes NW; Skelly JP
    Pharm Res; 1989 Apr; 6(4):346-51. PubMed ID: 2748524
    [No Abstract]   [Full Text] [Related]  

  • 25. Transdermal clonidine: therapeutic considerations.
    Sica DA; Grubbs R
    J Clin Hypertens (Greenwich); 2005 Sep; 7(9):558-62. PubMed ID: 16227779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of transdermal therapy with clonidine on suppression symptoms secondary to smoking cessation].
    Cervantes Escárcega JL; Guadalajara Boo JF
    Arch Inst Cardiol Mex; 1992; 62(5):435-40. PubMed ID: 1482222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hypertension by a new transdermal form of clonidine.
    Gosse P; Wicker P; Roudaut R; Danays T; Dallocchio M
    J Hypertens Suppl; 1985 Dec; 3(4):S65-7. PubMed ID: 3868714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin pretreatment and the use of transdermal clonidine.
    Ito MK; O'Connor DT
    Am J Med; 1991 Jul; 91(1A):42S-49S. PubMed ID: 1831005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral bioavailability of clonidine in children.
    Larsson P; Nordlinder A; Bergendahl HT; Lönnqvist PA; Eksborg S; Almenrader N; Anderson BJ
    Paediatr Anaesth; 2011 Mar; 21(3):335-40. PubMed ID: 20735802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal clonidine: does it affect pain after abdominal hysterectomy?
    Dimou P; Paraskeva A; Papilas K; Fassoulaki A
    Acta Anaesthesiol Belg; 2003; 54(3):227-32. PubMed ID: 14598620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial.
    Ornish SA; Zisook S; McAdams LA
    Arch Intern Med; 1988 Sep; 148(9):2027-31. PubMed ID: 3046542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension--a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators.
    Clin Auton Res; 1993 Dec; 3(6):379-83. PubMed ID: 8193525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with rate-controlled delivery of antihypertensive therapy by a transdermal system.
    Weber MA; Drayer JI
    Am Heart J; 1984 Jul; 108(1):231-6. PubMed ID: 6375331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of clonidine in high dosage.
    Fauler J; Verner L
    Eur J Clin Pharmacol; 1993; 45(2):165-7. PubMed ID: 8223840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of menopausal hot flashes with transdermal administration of clonidine.
    Nagamani M; Kelver ME; Smith ER
    Am J Obstet Gynecol; 1987 Mar; 156(3):561-5. PubMed ID: 3826200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetics of clonidine following intravenous administration of high doses for the treatment of delirium tremens].
    Rominger KL; Schäfer E; Vrecko HG; Palme M
    Arzneimittelforschung; 1991 Apr; 41(4):399-401. PubMed ID: 1859513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers.
    Krishnaiah YS; Al-Saidan SM; Chandrasekhar DV; Satyanarayana V
    J Control Release; 2005 Aug; 106(1-2):111-22. PubMed ID: 15993975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A community-based trial of transdermal antihypertensive therapy with clonidine (Catapres-TTS).
    Kellaway GS; Lubbe WF
    N Z Med J; 1986 Sep; 99(810):711-4. PubMed ID: 3547202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of application site of a new transdermal clonidine, M-5041T, on its pharmacokinetics and pharmacodynamics in healthy subjects.
    Ebihara A; Fujimura A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1188-91. PubMed ID: 8126253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.